AKTX - アカリ・セラピュ―ティクス (Akari Therapeutics Plc)

AKTXのニュース

   Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Above 50 Day Moving Average of $1.62  2021/12/24 07:54:41 Dakota Financial News
Akari Therapeutics, Plc (NASDAQ:AKTX)s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.62 and traded as high as $1.64. Akari Therapeutics shares last traded at $1.54, with a volume of 75,065 shares traded. The company has a market cap of $73.30 million, []
   Akari Therapeutics reports Q3 results  2021/12/03 12:55:18 Seeking Alpha
   Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress  2021/12/03 12:45:00 Intrado Digital Media
NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the third quarter of 2021 and recent clinical progress.
   Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders  2021/12/01 13:30:00 Intrado Digital Media
Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia
   Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Decreases By 74.4%  2021/11/29 06:30:47 Dakota Financial News
Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 15,700 shares, a drop of 74.4% from the October 31st total of 61,300 shares. Based on an average daily volume of 113,700 shares, the short-interest ratio is []
   Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference  2021/09/22 13:00:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET.
   Akari Therapeutics reports Q2 results  2021/09/22 12:43:36 Seeking Alpha
   Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress  2021/09/22 12:30:00 Benzinga
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP). Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment. Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD). Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung. Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to nomacopan. NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress.
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:34 Investor Akaritx
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Companys Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid (BP) at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium.
   Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference  2021/09/22 13:00:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET.
   Akari Therapeutics reports Q2 results  2021/09/22 12:43:36 Seeking Alpha
   Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress  2021/09/22 12:30:00 Benzinga
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP). Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment. Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD). Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung. Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to nomacopan. NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress.
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:34 Investor Akaritx
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Companys Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid (BP) at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium.

calendar